Last reviewed · How we verify
Tuvusertib [14C]Tuvusertib microtracer — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Tuvusertib [14C]Tuvusertib microtracer (Tuvusertib [14C]Tuvusertib microtracer) — Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tuvusertib [14C]Tuvusertib microtracer TARGET | Tuvusertib [14C]Tuvusertib microtracer | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tuvusertib [14C]Tuvusertib microtracer CI watch — RSS
- Tuvusertib [14C]Tuvusertib microtracer CI watch — Atom
- Tuvusertib [14C]Tuvusertib microtracer CI watch — JSON
- Tuvusertib [14C]Tuvusertib microtracer alone — RSS
Cite this brief
Drug Landscape (2026). Tuvusertib [14C]Tuvusertib microtracer — Competitive Intelligence Brief. https://druglandscape.com/ci/tuvusertib-14c-tuvusertib-microtracer. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab